AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
Starting June 1, 2024, eligible patients will pay no more than $35 per month for the following AstraZeneca inhalers: Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort. The savings ...
Viatris announced the launch of Breyna ™ (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca’s Symbicort ®. Breyna is a metered-dose inhaler ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback